Serina Therapeutics Reports $13.3 Million Net Loss, Cash Reserves Increase to $23 Million

Serina Therapeutics, Inc. reported a net loss of $13.3 million for the six months ending June 30, 2026, compared to a loss of $11.3 million for the same period in 2025. The company did not generate any revenue during the current fiscal period, a decrease from $130,000 in grant revenues reported in the previous year. Total operating expenses increased to $13.1 million from $11.6 million, driven primarily by higher research and development costs, which rose to $7.0 million from $6.1 million, and general and administrative expenses, which increased to $6.0 million from $5.4 million.

In terms of financial position, Serina's cash and cash equivalents surged to $23.0 million as of June 30, 2026, up from $3.1 million at the end of 2025. This increase was largely attributed to successful financing activities, including $21.1 million raised through a private placement in March 2026 and $10.2 million from an at-the-market (ATM) program. The company’s total assets also rose significantly to $25.8 million from $7.0 million at the end of 2025, reflecting a substantial improvement in liquidity.

Operationally, Serina has made strides in advancing its clinical programs, particularly with its lead product candidate, SER-252, which is designed to treat advanced Parkinson’s disease. The company has initiated a Phase 1b clinical study for SER-252, following the clearance of its Investigational New Drug (IND) application by the FDA in January 2026. The company’s employee headcount has also increased, reflecting its commitment to expanding its research and development capabilities.

Despite these advancements, Serina continues to face significant challenges, including the need for additional capital to fund ongoing operations and development activities. The company has expressed substantial doubt about its ability to continue as a going concern, given its history of operating losses and the anticipated need for further financing. Management indicated that it expects to incur substantial expenditures in the foreseeable future, particularly as it seeks regulatory approvals for its product candidates and expands its workforce.

Looking ahead, Serina plans to continue its focus on advancing its clinical programs and securing additional funding. The company aims to leverage its proprietary POZ drug delivery technology to enhance the efficacy and safety profiles of its drug candidates. However, the path to commercialization remains uncertain, and the company will need to navigate various risks associated with clinical development and regulatory approval processes.